CSL shares (ASX: CSL) capped off a mighty third-quarter recovery with a 60.55% gain, closing September at A$184.22. There are a couple of technical signals raising leaving a few to question whether the easy money has already been made here, if there was such a thing.
The CSL share price rounded out the final session of Q3 up 1.05% at A$184.22, completing a quarter that saw the stock more than double off its 52-week low of A$90.00 set in June. The magnitude of the recovery has been striking by any measure, transforming what had been one of the ASX’s most high-profile underperformers into one of its standout stories of the year.
From a technical standpoint, the rally has pushed the stock’s RSI to 70.77, crossing the widely watched 70-level threshold that signals overbought conditions. A Golden Cross formation in mid-September, where the 50-day moving average crossed above the 200-day moving average provided the confirmation that accumulation was underway, and momentum has held firmly above former resistance at A$175 since. While the chart structure remains constructive, the RSI reading suggests the pace of gains may need to cool off.
Recent Financials
The catalyst for CSL’s sharp re-rating was its full-year results release, in which management framed FY26 as a deliberate “reset year” for the business. Group revenue came in at US$15.8 billion, with underlying net profit after tax (NPATA) of US$3.1 billion, marginally ahead of market expectations. Operational cash flow reached a robust US$3.5 billion, underpinning management’s decision to announce a new US$1.1 billion share buyback for FY27, following a US$1.0 billion buyback in FY26. The full-year dividend was maintained at US$2.92 per share.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The headline result masked a significant non-cash impairment charge of US$7.1 billion, primarily related to the 2022 acquisition of CSL Vifor, which has struggled under intensifying generic competition in its iron deficiency product portfolio. The write-down produced a statutory net loss of US$2.6 billion for FY26 and confirmed that the Vifor acquisition has not delivered the synergies originally anticipated. Management now expects CSL Vifor revenue to decline approximately 25% in FY27, making it a meaningful drag on top-line momentum.
The core plasma business, CSL Behring, remained the operational backbone of the result. A recovery in plasma collection volumes, combined with cost savings of US$176 million that exceeded internal targets, helped restore confidence in the division’s margin trajectory. For FY27, CSL is guiding for group revenue to remain broadly flat on a constant-currency basis, while projecting underlying NPAT growth of approximately 5%, driven by mid-single-digit growth from CSL Behring.
Beyond the financials, CSL has been active on the strategic front. The company confirmed the completion of its Seqirus operational separation and officially opened a state-of-the-art cell-based influenza vaccine manufacturing facility in Tullamarine, Melbourne. The facility reinforces CSL’s position as the world’s second-largest influenza vaccine producer and supports long-term sovereign supply arrangements. Seqirus is expected to deliver low-single-digit revenue growth in FY27.
In a separate development that captured broader market attention, CSL announced a multi-year partnership with Amazon Web Services to integrate artificial intelligence and machine learning capabilities across its global R&D pipeline. The initiative targets faster drug discovery workflows, improved clinical trial data analytics, and optimised plasma collection logistics. While the financial impact is unlikely to be material in the near term, the partnership signals a deliberate effort to embed technology-driven efficiency gains into the business over the medium to long term.
What Could Q4 Hold In Store
Broker sentiment heading into Q4 remains broadly constructive, with 11 of 19 analysts maintaining Buy or Strong Buy ratings on the stock. However, the average price target now sits marginally below the current share price. At current levels, CSL is trading at 20 times FY27 estimated earnings, a valuation that reflects a meaningful jump from the lows but leaves limited margin of safety if execution stumbles.
From a technical perspective, the Golden Cross remains a positive structural signal, and the stock’s ability to hold above A$175 will be closely watched as a key support level. A period of consolidation or modest pullback from overbought levels would not be unusual following a rally of this magnitude, and could ultimately provide a healthier foundation for any further advance.
Bull Case:
- Golden Cross confirms structural shift from bear market to institutional accumulation phase.
- US$3.5 billion operational cash flow and US$1.1 billion buyback signal strong capital discipline.
- US$7.1 billion Vifor impairment clears balance sheet uncertainty, removing a key valuation overhang.
- AWS AI partnership positions CSL for long-term R&D efficiency and drug discovery acceleration.
Bear Case:
- Consensus price target of A$182.85 sits below current share price, limiting near-term upside.
- RSI of 70.77 signals overbought conditions, raising short-term profit-taking risk.
- FY27 revenue broadly flat; earnings growth relies on cost-cutting rather than top-line expansion.
- CSL Vifor revenue expected to fall 25% in FY27, confirming acquisition underperformance continues.
